WSTAM
KIN

Wilbanks Smith & Thomas Asset Management’s Kindred Biosciences, Inc. KIN Stock Holding History

Wilbanks Smith & Thomas Asset Management’s Portfolio KIN Stock Details KIN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-100
Closed -$1K – 1451
2018
Q3 		$1K Buy
+100
New +$1.35K ﹤0.01% 1585

Other funds holding KIN

PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wilbanks Smith & Thomas Asset Management's KIN Position: Q4 2018 in Review

Wilbanks Smith & Thomas Asset Management sold out of Kindred Biosciences, Inc. (KIN) in Q4 2018, closing a stake of 100 shares — an estimated $1K sold.

Wilbanks Smith & Thomas Asset Management first reported a position in KIN in Q3 2018 and held it in 1 quarter. The position peaked at $1K in Q3 2018. 72 funds tracked by Wall St. Rank hold KIN as of Q4 2018.

  • Wilbanks Smith & Thomas Asset Management reported no remaining Kindred Biosciences, Inc. position as of Q4 2018 after selling out during the quarter.
  • Wilbanks Smith & Thomas Asset Management sold 100 Kindred Biosciences, Inc. shares in Q4 2018, an estimated $1K.
  • Wilbanks Smith & Thomas Asset Management first reported a position in Kindred Biosciences, Inc. in Q3 2018 and held it in 1 quarter.
  • Wilbanks Smith & Thomas Asset Management's Kindred Biosciences, Inc. position peaked at $1K in Q3 2018.
  • 72 funds tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q4 2018.

Based on Wilbanks Smith & Thomas Asset Management's 13F filing for Q4 2018, filed 8 Feb 2019.